E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of RSV Illness |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061603 |
E.1.2 | Term | Respiratory syncytial virus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of a single IM dose of MEDI7510 for the prevention of acute respiratory syncytial virus-associated respiratory illness (ARA-RI) in adults ≥ 60 years of age in Season 1 of dosing. |
|
E.2.2 | Secondary objectives of the trial |
1. To assess the safety and tolerability of MEDI7510 in Season 1 and Season 2
2. To assess the incidence of RSV polymerase chain reaction (PCR)-positive respiratory
illness in Season 1
3. To assess the immunogenicity of inactivated influenza vaccine (IIV) administered alone
as compared to administered concurrently with MEDI7510 in Season 1
4. To assess the immune response to MEDI7510 in Season 1 and Season 2 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Season 1
1. Age ≥ 60 years at the time of screening.
2. Written informed consent and any locally required authorization (eg, Health Insurance
Portability and Accountability Act) obtained from the subject prior to performing any
protocol-related procedures, including screening evaluations.
3. Medically stable such that, according to the judgment of the investigator, hospitalization
within the study period is not anticipated and the subject appears likely to be able to
remain in follow-up through the end of protocol-specified follow-up.
4. Subject able to visit the clinic for study-specified visits and subject also available by
telephone.
5. Subject able to understand and comply with the requirements of the protocol.
6. Subject able to complete study follow-up period in Season 1 and, according to investigator judgment, reasonably likely to complete the study follow-up period in Season 2 if assigned.
Season 2
1. Subject received MEDI7510 + IIV in the Northern Hemisphere in Season 1.
2. Subject able to visit the clinic for study-specified visits and subject also available by
telephone.
3. Subject able to understand and comply with the requirements of the protocol. |
|
E.4 | Principal exclusion criteria |
Season 1
1. History of allergy to any component of the vaccine.
2. Receipt of seasonal influenza vaccine within 6 months prior to Season 1 dosing.
3. History of allergy to or intolerance of IIV.
4. Pregnancy or potential to become pregnant during the study.
5. History of Guillain-Barré syndrome.
6. Cognitive disorder such that informed consent cannot be obtained directly from the
subject.
7. Previous vaccination against RSV.
8. History of allergy to eggs in adulthood.
9. History of or current autoimmune disorder, with the exception of stable, treated hypothyroidism caused by autoimmune thyroiditis.
10. Immunosuppression caused by disease, including human immunodeficiency virus
infection (assessed by history), or medications. Any receipt of oral or intravenous
glucocorticoid therapy within 30 days prior to enrollment or planned dosing within the
follow-up period would disqualify. Topical, intranasal, inhaled, or intra-articular
corticosteroids do not disqualify. Expected need for immunosuppressive medications
during the follow-up period would disqualify.
11. History of cancer within preceding 5 years other than treated non-melanoma skin cancer,
locally-treated cervical cancer or in situ carcinoma of the breast.
12. Significant infection or other acute illness, including fever ≥ 100°F (≥ 37.8°C) on the day
prior to or day of randomization.
13. Receipt of any non-study vaccine within 28 days prior to study dosing or expected receipt
of non-study vaccine prior to the Day 29 visit in Season 1.
14. Receipt of any investigational product in the 90 days prior to randomization or expected
receipt of investigational product during the period of study follow-up.
15. Receipt of immunoglobulins or blood products within 4 months of study dosing
(120 days) or expected receipt of immunoglobulins or blood products during the period
of study follow-up.
16. Current bleeding or clotting disorder including use of anticoagulants other than drugs
with anti-platelet activity (such as nonsteroidal anti-inflammatory drugs, clopidogrel,
ticagrelor or aspirin).
17. Any condition that, in the opinion of the investigator, would interfere with evaluation of
the investigational product or interpretation of subject safety or study results.
18. History of alcohol or drug abuse or psychiatric disorder that, in the opinion of the
investigator, would affect the subject’s safety or compliance with study.
Season 2
1. Related Grade 3 or 4 AE including Grade 3 or 4 local reaction to either MEDI7510 or
IIV, any AESI for an adjuvanted vaccine, or any related SAE. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The incidence of the first episode of ARA-RI observed during the RSV surveillance period in
Season 1. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At least 14 days after vaccination and during the RSV surveillance period. |
|
E.5.2 | Secondary end point(s) |
- The occurrence of all solicited symptoms (whether or not treatment-emergent) and
treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events
(TESAEs), new onset chronic diseases (NOCDs), and treatment-emergent adverse events
of special interest (TEAESIs) in Seasons 1 and 2
- The incidence of RSV PCR-positive respiratory illness during the RSV surveillance
period in Season 1
- The post-dose geometric mean titers (GMTs) and geometric mean fold rises (GMFRs)
from baseline of strain-specific hemagglutination inhibition (HAI) antibodies to influenza
antigens contained in the seasonal influenza vaccine received by subjects in the IIV
immunogenicity subset; in addition, the proportion of subjects in the IIV immunogenicity
subset who had a by-strain post-dose seroresponse to HAI antibody, defined as ≥ 4-fold
rise from baseline
- The immune response to MEDI7510 in Seasons 1 and 2 in subjects in the RSV
immunogenicity subset |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Solicited symptoms: Day 1 through Day 7 Seasons 1 and 2
- TEAE/TESAE/NOCD/TEAESIs: Day 1 through final Season 1 contact and/or Last Contact Season 2
- Incidence of RSV-PCR positive respiratory illness: At least 14 days after vaccination and during the RSV surveillance period.
- HAI: Day 29 Season 1
- Immune response: Dosing through Last Contact Season 2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Locally approved and marketed Inactivated Influenza Vaccine (IIV) administered per label |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Chile |
Estonia |
Latvia |
Lithuania |
South Africa |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is last subject last visit in Season 2 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |